Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2636-2640

  Geller, David E ^a   Flume, Patrick A ^b   Griffith, David C ^c   Morgan, Elizabeth ^c   White, Dan ^c   Loutit, Jeffery S ^c   Dudley, Michael N ^c  

^a NEMOURS CHILDREN S HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Mpex Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEROQUIN; LEVOFLOXACIN; MP 376; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SPUTUM LEVEL; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; HEMOPTYSIS; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NEBULIZATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SPUTUM ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; SINGLE-BLIND METHOD; SOLUTIONS;

EID: 79956336460     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01744-10     Document Type: Article

References (12)

1. Ambrose, P. G., et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
2. Conrad, D., et al. 2010. Phase 2b study of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection, abstr. A102. Am. J. Respir. Crit. Care Med. 181(Meeting abstr.):A2339.
3. Geller, D. E., et al. 2006. Pharmacokinetics of oral levofloxacin (LVX) in stable adult CF subjects. Pediatr. Pulmonol. 41(S29):328.
4. Geller, D. E. 2008. The science of aerosol delivery in cystic fibrosis. Pediatr. Pulmonol. 43(Suppl. 9):S5-S17.
5. Gibson, R. L., J. L. Burns, and B. W. Ramsey. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168:918-951.
6. Griffith, D. C., et al. 2006. Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy? Antimicrob. Agents Chemother. 50:1628-1632.
7. Jumbe, N., et al. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112:275-285.
8. King, P., O. Lomovskaya, D. C. Griffith, J. L. Burns, and M. N. Dudley. 2010. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob. Agents Chemother. 54:143-148.
9. King, P., et al. 2008. In vitro PK-PD of levofloxacin (LVX): a new dosing paradigm for aerosolized antibiotics, abstr. A-042. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Preston, S., et al. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129. (Pubitemid 28068302)
11. Sabet, M., et al. 2009. Efficacy of aerosol MP-376 (levofloxacin inhalation solution) in mouse lung infection models due to Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:3923-3928.
12. Tam, V. H., et al. 2005. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J. Infect. Dis. 192:420-428.